Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | NOS2 | P35228 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.33 |
| ▸ | ADH1B | P00325 | 1/20 | 0.31 |
| ▸ | ADH1C | P00326 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5646119 | 0.91 | SLC6A2 (0.36) | NOS3NOS1NOS2SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL28747733 | 0.89 | SLC6A2 (0.35) | NOS3NOS1NOS2SLC6A2SLC6A4 | |
| SCHEMBL12362618 | 0.83 | NOS2 (0.38) | NOS3NOS1NOS2SLC6A2SLC6A4 | |
| SCHEMBL24242503 | 0.83 | NOS2 (0.38) | NOS3NOS1NOS2SLC6A2SLC6A4 | |
| SCHEMBL10093885 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL20362240 | 0.82 | NOS2 (0.37) | NOS3NOS1NOS2SLC6A2SLC6A4 | |
| SCHEMBL104779 | 0.79 | ADH1A (0.44) | ADH1BADH1CADH1A | |
| SCHEMBL8434628 | 0.78 | SLC6A4 (0.38) | NOS3NOS1NOS2SLC6A2SLC6A4 | |
| SCHEMBL22215286 | 0.78 | SLC6A4 (0.38) | NOS3NOS1NOS2SLC6A2SLC6A4 | |
| SCHEMBL14196261 | 0.78 | SLC6A4 (0.38) | NOS3NOS1NOS2SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414763-B2 | Azaquinazoline inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
| US-7667052-B2 | Bioactive substance | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414763-B2 | Azaquinazoline inhibitors of atypical protein kinase C | PRKCQ, PRKCA, PRKCZ | NOS3 3277/4885NOS1 3314/4885NOS2 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.